Fatal outcome of a hypersensitivity reaction to paclitaxel: a critical review of premedication regimens

被引：108

作者：

Kloover, JS

den Bakker, MA

Gelderblom, H

van Meerbeeck, JP

机构：

[1] Erasmus MC, Dept Pulmonol, NL-3000 CA Rotterdam, Netherlands

[2] Erasmus MC, Josephine Nefkens Inst, Dept Pathol, Rotterdam, Netherlands

[3] LUMC, Dept Clin Oncol, Leiden, Netherlands

[4] Univ Hosp, Dept Resp Dis, Ghent, Belgium

来源：

BRITISH JOURNAL OF CANCER | 2004年 / 90卷 / 02期

关键词：

paclitaxel; hypersensitivity reaction; anaphylaxis; dexamethasone; premedication;

D O I：

10.1038/sj.bjc.6601303

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

Hypersensitivity reactions (HSRs) to paclitaxel are frequently encountered in patients receiving this antitumour drug. Administration of histamine H1- and H2-receptor antagonists and corticosteroids has been shown to reduce significantly the risk of developing an HSR in patients receiving taxanes. In this case report, we describe the fatal outcome of an HSR in a patient receiving paclitaxel despite short-course premedication. the level of evidence supporting the short-course i.v. premedication schedule is challenged, as it is not compatible with the pharmacokinetic properties of dexamethasone.

引用

收藏

页码：304 / 305

页数：2

相关论文

共 17 条

[1]

Short-course intravenous prophylaxis for paclitaxel-related hypersensitivity reactions [J].

Bookman, MA ;

Kloth, DD ;

Kover, PE ;

Smolinski, S ;

Ozols, RF .

ANNALS OF ONCOLOGY, 1997, 8 (06) :611-614

[2]

SUSPECTED ANAPHYLACTIC REACTION TO CREMOPHOR EL [J].

DYE, D ;

WATKINS, J .

BRITISH MEDICAL JOURNAL, 1980, 280 (6228) :1353-1353

[3]

Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation [J].

Gelderblom, H ;

Verweij, J ;

Nooter, K ;

Sparreboom, A .

EUROPEAN JOURNAL OF CANCER, 2001, 37 (13) :1590-1598

[4]

Kintzel PE, 2001, ANN PHARMACOTHER, V35, P1114

[5]

Dose reduction of steroid premeditation for paclitaxel:: No increase of hypersensitivity reactions [J].

Köppler, H ;

Heymanns, J ;

Weide, R .

ONKOLOGIE, 2001, 24 (03) :283-285

[6]

Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: A phase III randomized trial [J].

Kosmidis, P ;

Mylonakis, N ;

Nicolaides, C ;

Kalophonos, C ;

Samantas, E ;

Boukovinas, J ;

Fountzilas, G ;

Skarlos, D ;

Economopoulos, T ;

Tsavdaridis, D ;

Papakostas, P ;

Bacoyiannis, C ;

Dimopoulos, M .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (17) :3578-3585

[7]

A comparison of two prophylactic regimens for hypersensitivity reactions to paclitaxel [J].

Kwon, JS ;

Elit, L ;

Finn, M ;

Hirte, H ;

Mazurka, J ;

Moens, F ;

Trim, K .

GYNECOLOGIC ONCOLOGY, 2002, 84 (03) :420-425

[8]

An effective and more convenient drug regimen for prophylaxis against paclitaxel-associated hypersensitivity reactions [J].

Markman, M ;

Kennedy, A ;

Webster, K ;

Peterson, G ;

Kulp, B ;

Belinson, J .

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 1999, 125 (07) :427-429

[9]

Single-dose dexamethasone paclitaxel premedication [J].

Micha, JP ;

Rettenmaier, MA ;

Dillman, R ;

Fraser, P ;

Birk, C ;

Brown, JV .

GYNECOLOGIC ONCOLOGY, 1998, 69 (02) :122-124

[10]

Pharmacokinetics of dexamethasone and its relationship to dexamethasone suppression test outcome in depressed patients and healthy control subjects [J].

OSullivan, BT ;

Cutler, DJ ;

Hunt, GE ;

Walters, C ;

Johnson, GF ;

Caterson, ID .

BIOLOGICAL PSYCHIATRY, 1997, 41 (05) :574-584